Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 65 years of age, scheduled for hernia repair surgery~* Patients must be in good health prior to study participation~* Patients must have blood pressure within normal range or with Stage 1 high blood pressure~* Male and female patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial is completed~* Patients must refrain from strenuous activities and avoid changes to prescribed exercise levels throughout the course of the trial~* Ability to read, understand, communicate, and voluntarily sign the informed consent form prior to any trial specific procedures~Exclusion Criteria:~* Patients with previous abdominal surgery scar tissue~* Patients with clinically significant abnormalities of any body system unrelated to the disease under study~* Connective tissue disorders~* Patients who are pregnant or lactating~* Current or regular use of analgesic medication for other indications~* Patients with current or regular use of antidepressants or monoamine oxidase inhibitors at screening~* Use of any drugs or medication that may interfere with the study and its results~* Patients with known hypersensitivity to the study drugs or their components~* Patients with known or suspected alcohol abuse or illicit drug use~* Participation in another clinical trial at the same time or within 30 days of this trial~* Patient is unwilling to comply with the study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: SABER-Bupivacaine (Type: EXPERIMENTAL): 2.5 mL SABER-Bupivacaine/Once
- Group 2: SABER-Bupivacaine (Type: EXPERIMENTAL): 5.0 mL SABER-Bupivacaine/Once
- Group 3: SABER-Placebo (Type: PLACEBO_COMPARATOR): 2.5 mL or 5.0 mL SABER-Placebo/Once

Based on this trial design, predict the completion outcome and termination type (if applicable).